ClinicalTrials.gg
CompletedNCT068277563C-SPSUpdated Feb 14, 2025

Comparative Study of Secondary Prophylaxis for SBP

A Phase 4 interventional study of Norfloxacin 400 MG and Nitazoxanide 500 MG in Spontaneous Bacterial Peritonitis, Cirrhoses, Liver and Ascites, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Tanta University · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Mar 2021, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Ascites with a site in Egypt — 2 open to participants now, 2 under way, 1 of them phase 3. Ascites · Egypt.

Started
2021
with 1 other
Phase 4
Only one
of the 13
Registered
11th of 13
by date
Lead sponsor
2 of 13
Tanta University

Among the 13 studies in Ascites with a site in Egypt, this one is one of 2 that started in 2021, is the only one in phase 4, and was the 11th registered.

Ascites

248 studies on the registry are indexed under Ascites; 57 are open to participants now.

Browse Ascites studies →

Open to participants now

2 of the 13 studies in Ascites with a site in Egypt are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 40 Ascites studies recruiting now, 21 (53%) set no upper age limit and 12 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Ascites with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if norfloxacin, nitazoxanide, and colistin work as secondary prophylactic agents for spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites. It also aims to evaluate the safety and effectiveness of these treatments. The main questions it aims to answer are:

Are nitazoxanide and colistin as effective as norfloxacin in preventing recurrent SBP?

What medical outcomes do participants experience when taking norfloxacin, nitazoxanide, or colistin?

Researchers will compare norfloxacin, nitazoxanide, and colistin to determine their effectiveness in preventing SBP recurrence in cirrhotic patients.

Participants will:

Be randomly assigned to receive either 400 mg norfloxacin daily, 500 mg nitazoxanide twice daily, or 15 ml colistin syrup three times daily (2.25 MIU total per day).

Undergo regular blood tests and ascitic fluid analysis at discharge, 2 months, and 6 months post-treatment.

Be monitored for any side effects and recurrence of SBP.

03

Conditions studied

  • Spontaneous Bacterial Peritonitis
  • Cirrhoses, Liver
  • Ascites

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Success Criteria: A ≥50% reduction in CRP within 3 months is considered a positive response.

  • Ascitic patients diagnosed with Spontaneous Bacterial Peritonitis (SBP) by paracentesis.
  • Ascitic fluid polymorphonuclear (PMN) cell count > 250/mm³.
  • Age 50 years to 80 years.
  • Willing to provide .

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females.
  • History of allergic reactions to Norfloxacin, Nitazoxanide, or Colistin.
  • Patients with recurrent spontaneous peritonitis.
  • Presence of gastrointestinal hemorrhage.
  • Renal failure (Creatinine > 2 mg/dL or on dialysis).
  • Presence of severe infection-related sequelae (e.g., persistent fever, abdominal discomfort, sepsis).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Norfloaxcin arm

    patients to receive norflxacin 400mg daily

    Drug: Norfloxacin 400 MG

  • Active comparator
    Nitazoxaide arm

    patients to receive nitazoxaide 500mg daily

    Drug: Nitazoxanide 500 MG

  • Active comparator
    Colisitn arm

    patients to receive Colistin 15 ml three times daily, totalling 2,25 MIU/ day

    Drug: Colistin

Interventions

  • Patients receiving Norfloxacin 400 Mg to prevent SBP

  • Patients receiving Nitazoxaide 500 Mg to prevent SBP

  • Patients receiving Colistin 15ml three times/ day to prevent SBP

06

What researchers measure

Primary outcomes

  1. Recurrence of Spontaneous Bacterial Peritonitis (SBP)

    Definition: The percentage of patients experiencing a recurrence of SBP within 6 months of treatment initiation. Measurement: Diagnosis confirmed by ascitic fluid analysis (PMN count \> 250 cells/mm³ and positive culture).

    Time frame: Baseline, 3 months, and 6 months

Secondary outcomes

  1. C-Reactive Protein (CRP) Reduction

    Definition: A decrease in CRP levels, indicating a reduction in systemic inflammation. Measurement: CRP levels measured in mg/L. Success Criteria: A ≥50% reduction in CRP within 3 months is considered a positive response.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  2. White Blood Cell (WBC) Count Reduction

    Definition: Reduction in WBC count as a marker of infection control. Measurement: WBC count measured in x10³/µL. Success Criteria: A return to normal WBC count (\<10,000/µL) by 3 months.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  3. Renal Function Stability

    Definition: Prevention of renal impairment during treatment. Measurement: Serum Creatinine (mg/dL) and Blood Urea Nitrogen (BUN) (mg/dL).

    Time frame: Baseline, 3 months, and 6 months

Other outcomes

  1. Adverse Events (Safety Assessment)

    Definition: Frequency and severity of treatment-related side effects (e.g., diarrhea, nephrotoxicity, hypersensitivity reactions). Measurement: Patient-reported symptoms and clinical examination findings.

    Time frame: Throughout study duration (0-6 months)

07

Study locations

1 site
  • Tanta University, Faculty of Medicine
    Tanta, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Dec 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 14, 2025
StartActual
Mar 1, 2021
Primary completionActual
Dec 1, 2021
CompletionActual
Feb 1, 2022
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06827756
Lead sponsor
Tanta University
Responsible party
Dina Ahmed Esmat (Resident, Tanta University) — Principal investigator
First posted
Feb 14, 2025
Start date
Mar 1, 2021
Primary completion
Dec 1, 2021
Completion
Feb 1, 2022
Last update
Feb 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Norfloxacin · Nitazoxanide · Colistin

Start the discussion